40 results about "Novobiocin" patented technology

Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.

Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders.

Novobiocin analogues useful as Hsp90 inhibitors in the treatment of cancer, neuroprotection, and autoimmune disorders.

Novel analogues and derivatives of novobiocin are provided, including compounds having modifications to the amide side chain, coumarin ring, and sugar moieties. The compounds of the present invention are useful as heat shock protein 90 inhibitors, and may be used as anticancer and neuroprotective agents.

We have made retrovirus particles displaying a functional antibody fragment. We fused the gene encoding an antibody fragment directed against a hapten with that encoding the viral envelope protein (Pr80env) of the ecotropic Moloney murine leukemia virus. The fusion gene was co-expressed in ecotropic retroviral packaging cells with a retroviral plasmid carrying the neomycin phosphotransferase gene (neo), and retroviral particles with specific hapten biding activities were recovered. Furthermore the hapten-binding particles were able to transfer the neo gene and the antibody-envelope fusion gene to mouse fibroblasts. In principle, the display of antibody fragments on the surface of recombinant retroviral particles could be used to target virus to cells for gene delivery, or to retain the virus in target tissues, or for the construction of libraries of viral display packages.

The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.

Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof.

This invention relates to several plasmids which are useful for genetically transforming plant cells. A first plasmid, such as pMON120, contains a T-DNA border, one or more marker genes, a unique cleavage site, and a region of Ti plasmid homology. A gene which is expressed in plant cells may be inserted into this plasmid to obtain a derivative plasmid, such as pMON128 which expresses neomycin phosphotransferase in plant cells. The derivative plasmid is inserted into a suitable microorganism, such as A. tumefaciens which contains a Ti plasmid. The inserted plasmids recombine with Ti plasmids to form co-integrate plasmids. Only a single crossover event is required to create the desired co-integrate plasmid. A. tumefaciens cells with co-integrate plasmids are selected and co-cultured with plant cells. The co-integrate Ti plasmids enter the plant cells and insert a segment of T-DNA which does not contain tumorigenic genes into the plant genome. The transformed plant cell(s) may be regenerated into a morphologically normal plant which will pass the inserted gene(s) to its descendants.

The invention discloses an application of a benzo Alpha-pyrone compound as a Gamma-type human herpes virus-resistant medicine. According to the invention, the compound resistant to Gamma-type human herpes virus infection is higher in activity as compared with a novobiocin which is a marketed medicine, and is less in toxicity based on a cytoxicity test. The compound can be used for curing or preventing related diseases caused by KSHV infection.

The invention discloses an eucommia ulmoides lignans and an application of eucommia ulmoides in preparation of Hsp90alpha inhibitor and anti-tumor drug, in particular to the application in preparationof heat shock protein 90 alpha (Hsp 90 alpha) selective C-terminal inbhibitor and use in preventing breast cancer and prostate cancer. The invention finds that the eucommia ulmoides lignans and its extractive extracted and prepared by using eucommia ulmoides as raw material can inhibit enzymatic activity of recombined human heat shock protein 90 alpha-C terminal; compared with a positive controldrug novobiocin, the eucommia ulmoides lignans show more excellent anti-cancer activity.

The appraisal method of glyphobacterium is a method of identification between bacteria species.It is a bacterial testing technology.At present, there are many tests used for identification of glyphobacterium species, complex steps, difficult to find, and less identification bacteria.The present invention uses 15 tests: oxidase, plasma coagulatases, neonomycin, chitosaccharides, VP, mananose, cotton sugar, eloarose, urea, natin, sucroseAlcohol has established the "Bacteria Identification Form", which overcomes the lack of previous methods.The specific technical solution is: (1) First test with oxidase, plasma coagulant, and texycin to determine the level of unknown staphylococci.(2) Use the test of internal connection at the level of the affiliation.(3) In contrast to the test results with the appraisal table, you can find the bacteria that you want to identify.The characteristics of the present invention: The operation is easy, the steps are clear, and the results are easy to check.Can be appraised for 30 species of bacteria.

The invention discloses a chromogenic medium and a chromogenic detection sheet capable of simultaneously detecting coliform and salmonella. The chromogenic medium contains peptone, yeast extract powder, beef extract powder, sodium chloride, sodium pyruvate, cholate, a specific enzyme chromogenic substrate, an enzyme inducer, a stabilizer, novobiocin and high molecular water-absorbent gel. The chromogenic medium is used for simultaneously detecting the coliform and the salmonella, is high in detection sensitivity, short in detection time and high in efficiency, and can simultaneously perform qualitative detection and quantitative detection and analysis on the coliforms and the salmonella, so that experimental operation is significantly reduced and the cost is saved; the chromogenic medium can be applied to direct sampling detection on tableware, food producing environment and equipment detection and other places; the coliform shows blue bacterial spots, and the salmonella shows red bacterial spots.

A method for prophylaxis or treatment of a mammal, particularly human, at risk for a fibrogenic disorder is disclosed. The compositions and methods of the invention are directed both to treatments for existing fibrogenic disorders and prevention thereof. Such disorders include, but are not limited to, connective tissue diseases, such as scleroderma (or systemic sclerosis), polymyositis, systemic lupus erythematosis and rheumatoid arthristis, and other fibrotic disorders, including liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. A therapeutic composition according to the invention includes, as a therapeutic agent, an inhibitor of a collagen promoter in a pharmaceutically acceptable inert carrier vehicle, preferably for local, and particularly topical, application. Exemplary inhibitors include those that interfere with heat shock protein 90 (Hsp 90) chaperone function, e.g., the specific inhibitor geldanamycin or other known Hsp90 inhibitors such as macbecin I and II, herbimycin, radcicol and novobiocin.

The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.

A construction method for a single knock-out mutant bacterial strain producing deoxynivalenol in a high-yield mode includes the following steps of firstly, knocking a negative regulatory factor high-affinity phosphodiesterase gene FgPDE2 generated in the fusarium graminearumout deoxynivalenol synthesis process out of a genome of fusarium graminearum PH-1 through a split-PCR method, and obtaining the single knock-out mutant, wherein the gene FgPDE2 and upstream and downstream sequences are shown in SEQ ID NO:1; secondly, PEG-mediated protoplast is converted into fusarium graminearum, knocking out converters through resistance screening and marker screening, and verifying that the target gene knocking out the converters is replaced with a neomycin resistance gene through primers 5F and 6R with the genome of fusarium graminearum serving as the reference. The toxicity production amount of the single knock-out mutant bacterial strain is greatly increased; the toxicity production amount of a double knock-out mutant bacterial strain is higher; the gene modification mutant loses the capacity for infecting wheatears, and negative effects caused by possible diffusion of the double knock-out mutant bacterial strain are greatly reduced.

A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.